Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Retained Earnings: 2023-2025

Historic Retained Earnings for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to -$431.1 million.

  • Monte Rosa Therapeutics' Retained Earnings rose 4.63% to -$431.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$431.1 million, marking a year-over-year increase of 4.63%. This contributed to the annual value of -$438.6 million for FY2024, which is 19.87% down from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Retained Earnings stood at -$431.1 million for Q3 2025, which was down 6.71% from -$404.0 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Retained Earnings high stood at -$262.6 million for Q1 2023, and its period low was -$452.0 million during Q3 2024.
  • Over the past 3 years, Monte Rosa Therapeutics' median Retained Earnings value was -$397.9 million (recorded in 2024), while the average stood at -$382.0 million.
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Retained Earnings crashed by 51.52% in 2024, and later increased by 5.65% in 2025.
  • Monte Rosa Therapeutics' Retained Earnings (Quarterly) stood at -$365.9 million in 2023, then dropped by 19.87% to -$438.6 million in 2024, then climbed by 4.63% to -$431.1 million in 2025.
  • Its Retained Earnings stands at -$431.1 million for Q3 2025, versus -$404.0 million for Q2 2025 and -$391.7 million for Q1 2025.